ML385

Name: ML385
Brand: MedChemExpress
SKU: HY-100523
Rating: 5.0 (351 reviews)

Cat. No.: HY-100523 Purity: 99.96%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC₅₀ of 1.9 μM.

For research use only. We do not sell to patients.

ML385 Chemical Structure

CAS No. : 846557-71-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 68	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 68	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 90	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 190	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 310	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 490	In-stock	Estimated Time of Arrival: December 31
200 mg	USD 750	In-stock	Estimated Time of Arrival: December 31
500 mg		Get quote
1 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 351 publication(s) in Google Scholar

339 Publications Citing Use of MCE ML385

RT-PCR

IHC

: ML385 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Feb 24;113:154726.; ML385 (10 μM; pretreate for 1 h) decreases Dehydroepiandrosterone (DHEA)-induced upregulation of nuclear Nrf2, HO-1 and NQO1 protein levels in both LMH cells and primary chicken hepatocytes.

: ML385 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 Apr 7;2019:3501059. [Abstract]; Immunofluorescence analysis of Nrf2 expression and nuclear translocation. Green fluorescence represents Nrf2, and blue fluorescence represents nucleus of hDPCs. Data represent mean ± standard deviations (n = 3).

: ML385 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 Apr 7;2019:3501059. [Abstract]; Western blot of Nrf2 and HO-1 protein expression levels with the treatment of HEMA, HEMA+BHQ, and HEMA+ML385.

: ML385 purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2019 Mar 18;2019:2853534. [Abstract]; The protein expression levels of Nrf2 (nucleus), Nrf2 (cytoplasm), HO-1, p-NF-κB p65, NF-κB p65, and ICAM-1 proteins are analyzed by Western blot with or without the treatment of H₂O₂, SAA and ML385.

: ML385 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 24;9(1):4429. [Abstract]; QPCR detecting NQO1 and GCLC genes in vector or HPV16 E7-expressing HaCaT cells treated with or without 10 μM ML385 for 24 h.

: ML385 purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2018 Oct;175(19):3747-3757. [Abstract]; Western blot of whole liver homogenate for p-JNK and 3-NT in mice with or without Chloroquine (CQ; 60 mg/kg) at 6 h.

: ML385 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Sep;155:494-509. [Abstract]; THP-1 cells are incubated with Cardamonin (30 μM), ML385 (5 μM) and ML385 + Cardamonin for 21 h, stimulated with LPS (2 μg/mL) for 3 h, and followed by ATP (5 mM) treatment for 30 min. The protein levels of NLRP3, cleaved caspase-1, ASC and cleaved IL-1β are detected by western blotting assay.

: ML385 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Dec 13;9:1444. [Abstract]; Seven days after the last MPTP intoxication, nucleus, and cytosol isolated from SNpc and striatum from all groups (sham, KOK, KOK+ML385, ML385, KOK, ML385) are subjected to Western blot assay to quantify changes in Nrf2 nuclear translocation and NQO1 expression, respectively.

: ML385 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Dec 13;9:1444. [Abstract]; Seven days after the last MPTP intoxication, SNpc and striatal sections (n = 3 per brain) are subjected to immunofluorescence staining using Nrf2 and NQO1 antibodies with the treatments (sham, KOK, KOK+ML385, ML385, KOK, ML385).

: ML385 purchased from MedChemExpress. Usage Cited in: Aging (Albany NY). 2018 Aug 16;10(8):2016-2036. [Abstract]; Relative changes in the expression of Nrf2, pNrf2 and HO-1 after treatment with D-gal, ML385 alone or combined with lycopene.

: ML385 purchased from MedChemExpress. Usage Cited in: Exp Gerontol. 2017 Dec 15;100:77-86. [Abstract]; Cells are treated with ML385 at the concentration of 5 μM for 12 h. The expression of Nrf2 and its translocation into nucleus are determined using western blot analysis.

: ML385 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2017 Dec 26;1864(3):882-890. [Abstract]; RAW264.7 cells are transfected with ML385 (5 μM) in the presence of Tan C (10 μM) for 24 h. Prdx1 and Nrf2 protein expression is determined by Western blotting

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor with an IC₅₀ of 1.9 μM.

IC₅₀ & Target

IC50: 1.9 μM (NRF2)^[1]

In Vitro

ML385 interacts with NRF2 and affects the DNA binding activity of the NRF2-MAFG protein complex. The addition of ML385 decreases anisotropy in a dose-dependent manner, with an IC₅₀ of 1.9 μM. A dose-dependent reduction in the NRF2 transcriptional activity is observed and the maximum inhibitory concentration is 5 μM by ML385. Treatment with ML385 leads to a significant reduction in NRF2 and downstream target gene expression selectively in KEAP1 mutant H460 cells. ML385 selectively affects the colony forming ability or growth of lung cancer cells with gain of NRF2 function^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ML385 in combination with carboplatin leads to a significant reduction in tumor cell proliferation, demonstrated by fewer Ki-67 positive cells. Tumor samples treated with ML385 show a significant reduction in NRF2 protein level and its downstream target genes^[1].
ML385 (intraperitoneal injection; 30 mg/kg; 7 days) weakens the therapeutic effects of MSC-Exo on inflammation-induced astrocytic activation in mice, and reduces reactive astrogliosis, NF-κB deactivation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old C57B/6 male mice^[3]
Dosage:	30 mg/kg; 7 days
Administration:	Intraperitoneal injection
Result:	Reversed inhibition of MSC-Exo on hippocampal astrocytic activation in vivo.

Molecular Weight

511.59

Formula

C₂₉H₂₅N₃O₄S

CAS No.

846557-71-9

Appearance

Solid

Color

White to yellow

SMILES

O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (48.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9547 mL	9.7735 mL	19.5469 mL
5 mM	0.3909 mL	1.9547 mL	3.9094 mL
10 mM	0.1955 mL	0.9773 mL	1.9547 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (3.91 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (19.55 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 9.01 mg/mL (17.61 mM); Suspended solution; Need ultrasonic
Protocol 3

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 5 mg/mL (9.77 mM); Suspended solution; Need ultrasonic
Protocol 4

Add each solvent one by one: 0.5% CMC/saline water
Solubility: 5 mg/mL (9.77 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (249 KB) HNMR (306 KB) LCMS (93 KB) Elemental Analysis Report (108 KB)

Handling Instructions (2659 KB)

References

[1]. Singh A, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. [Content Brief]

[2]. Xinnong Liu, et al. Isoliquiritigenin ameliorates acute pancreatitis in mice via inhibition of oxidative stress and modulation of the Nrf2/HO-1 pathway. Oxid Med Cell Longev. 20 March 2018.

[3]. Xian P, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice.Theranostics. 2019 Aug 14;9(20):5956-5975. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9547 mL	9.7735 mL	19.5469 mL	48.8673 mL
	5 mM	0.3909 mL	1.9547 mL	3.9094 mL	9.7735 mL
	10 mM	0.1955 mL	0.9773 mL	1.9547 mL	4.8867 mL
	15 mM	0.1303 mL	0.6516 mL	1.3031 mL	3.2578 mL
	20 mM	0.0977 mL	0.4887 mL	0.9773 mL	2.4434 mL
	25 mM	0.0782 mL	0.3909 mL	0.7819 mL	1.9547 mL
	30 mM	0.0652 mL	0.3258 mL	0.6516 mL	1.6289 mL
	40 mM	0.0489 mL	0.2443 mL	0.4887 mL	1.2217 mL

ML385 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ML385846557-71-9ML 385ML-385Keap1-Nrf2FerroptosisInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

ML385

Customer Review

ML385 Related Antibodies

339 Publications Citing Use of MCE ML385

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

ML385 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

ML385 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report